Sunil Agarwal has been appointed president of research and development for Seattle-based cancer immunotherapy company Juno Therapeutics (NASDAQ: [[ticker:JUNO]]), which has fallen behind its rivals in the race to produce the first commercial T cell therapy known as CAR-T. Before joining Juno, Agarwal was chief medical officer of Novato, CA-based Ultragenyx Pharmaceutical (NASDAQ: [[ticker:RARE]]). His experience also includes several senior leadership positions at Genentech.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
